Lozenge Intake
Phase 2Small molecule
Lozenge Intake is one of 11 small molecule programs targeting Oral leukoplakia. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Oral Leukoplakia
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Opdivo
Bristol-Myers SquibbPhase 2
Celebrex
PPhiladelphia Eye Associates
Phase 2
Glucophage
Boehringer IngelheimPhase 2
Pioglitazone Hydrochloride
Merck & Co.Phase 2
Rosiglitazone Maleate
GSKPhase 2
Acetylsalicylic Acid
BayerPhase 1
Photodynamic Therapy
RRoswell Park Cancer Institute
Phase 1
Aminolevulinic Acid Hydrochloride
MMayo Clinic
Phase 1
Lozenge Intake
UUniversity of Medicine and Dentistry of New Jersey
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lozenge Intake. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details